U.S. markets close in 2 hours 55 minutes

Accuray Incorporated (ARAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.4950+0.0250 (+0.56%)
As of 1:04PM EDT. Market open.
Sign in to post a message.
  • G
    Gregg
    Geisinger becomes first in U.S. to treat cancer patients with Accuray Synchrony® technology on the Radixact® and CyberKnife® S7™ Systems to better target radiation treatments

    ARAY
    -0.21%
    Mon, May 3, 2021, 4:30 AM

    ARAY
    -0.21%
    WILKES-BARRE, Pa. and SUNNYVALE, Calif., May 3, 2021 /PRNewswire/ -- Geisinger continues to bring advanced cancer care closer to home as it is the first hospital system in the U.S. to offer Accuray Incorporated's (NASDAQ: ARAY) newest Synchrony® technology on both the CyberKnife® S7™ and Radixact® Systems to better aim radiation beams and minimize damage to non-cancerous tissue during treatment.

    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)
    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)
    As part of Geisinger's expansion project at its Frank M. and Dorothea Henry Cancer Center, the health system recently began providing care using the one-of-a-kind Synchrony Motion Synchronization and Real-Time Adaptive Radiotherapy Technology on its CyberKnife S7 and Radixact Systems.

    Synchrony uses artificial intelligence to adapt radiation treatment delivery in real-time to tumor movement during the treatment session, with the goal of delivering a more targeted radiation dose to the tumor, in less time, to improve outcomes. Synchrony is designed to correct the radiation beam if a tumor moves because of bodily processes such as breathing or digestion, as well as patient movement that may occur during treatment.
    Bullish
  • T
    Terrence
    Expansion is starting to ramp up so I have no worries as the coming months is about to be very successful.
  • G
    Gregg
    Accuray Customers Achieve Top Scores in AAPM MArkerless Lung Target Tracking CHallenge (MATCH) Using Synchrony® Technology on the Radixact® and CyberKnife® Systems
    Thu, April 29, 2021, 4:30 AM

    ARAY
    -3.6735%
    - American Association of Physicists in Medicine (AAPM) Grand Challenge MATCH event was designed to evaluate the potential to track lung tumor motion without fiducial markers in real-time during radiation therapy

    - Results demonstrate exceptional accuracy is achievable with the Accuray-only Synchrony® Lung Tracking™ with Respiratory Modeling Technology

    SUNNYVALE, Calif., April 29, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Accuray customers took the top two positions in the MArkerless Lung Target Tracking CHallenge (MATCH) experimental branch using the Accuray Synchrony Lung Tracking with Respiratory Modeling on the Radixact® next-generation TomoTherapy® platform, and CyberKnife® System, respectively. The artificial intelligence (AI)-driven Synchrony technology is unique in using image guidance during radiation treatment delivery to detect motion and automatically adapt and synchronize radiation treatment in real-time with the movement of the target.

    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)
    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)
    The MATCH challenge applied a common measurement methodology to evaluate how closely each participant's tumor-tracking algorithm was able to follow the position of the phantom target over time. Scoring was based on how accurately and precisely each participant's radiation therapy system delivered the radiation beam in comparison to the location of the phantom target, based on its pre-specified, programmed motion.

    Accuray customers created treatment plans using the Synchrony markerless lung tracking algorithm on the Radixact and CyberKnife Systems to track targets in the anthropomorphically realistic lung phantom, as the targets moved according to motion traces that closely mimicked real clinical breathing patterns. The results showed that this tumor-tracking methodology is capable of accurately locating lung tumors throughout treatment without implanting any fiducial markers.

    "I'm grateful to have had the opportunity to test our approach for tracking lung tumor motion in the MATCH challenge. The results we achieved mirror those we have seen during the validation of the Synchrony technology on the Radixact System at our hospitals," said Lee Goddard, MPhys, DABR, physicist at Montefiore Health System and one of the team members involved in the effort. "As part of the process, more than 200 image-guided radiation therapy (IMRT) QA plans were delivered, with the majority being markerless (fiducial-free) lung tumor plans. We precisely tracked targets of various densities and shapes as they moved over the course of treatment delivery, improving the accuracy of radiation doses delivered."

    Story continues
  • A
    Anonymous
    Read the CC transcript. Opinion hasn't changed to be long on this. Numbers were OK but not bad by any means. Might dip back below 5 but that will be another opportunity to buy. Increasing R&D spending is a good sign and I support. They have 130M in cash, paid off 10M in term loan and generated 31M in FCF. They have a backlog of 611M. Current Market cap <500M is a great deal considering their Tech is very very good and can compete with the likes of anyone out there. GLTA
  • k
    kris
    IMHO not sure who is selling but Aray is in the right market in right time asia ...they have great tech and imo this is great opportunity to add at these oversold levels...it's a growth stock...do ur due diligence ...glta
  • p
    phing tre
    Current CEO at the helm too long, he makes progress but VAR is just too large to overcome.He needs some help for the like of Medtronic, Stryker, Fisher , or even GE. Time to get serious, too long much foot dragging
    Bullish
  • k
    kris
    IMHO very curious to know if it's the mms bringing the price lower with low volume...may be time to load up😀 do ur dd
  • J
    JeffreyT
    Bought $5 May calls. Really well priced. If numbers are good, I'll get to keep the shares. If they dissapoint, loss kept a minimum. I'm optimistic about the company, but realistic having followed it for a long time. Earnings and the reaction to them always unpredictable.
  • k
    kris
    IMHO simply underestimated stock ...with great tech and huge backlog and growing industry robotics which is future of medicine..plz do ur dd glta
  • T
    Terrence
    The Q results were not great but expected. With the recent news we have seen about expansion and results of their technology, the future looks promising.
  • J
    JeffreyT
    Did some journal reading over the weekend. In radiosurgery ARAY stands toe to toe with the gamma knife and Varian offerings. It’s a slow growth industry, but we have world class product. There is money to be made. Maybe not a fortune, but that’s ok.
  • t
    thomas
    Typical Aray. One step forward and 2 steps back. Just my opinion but I do not like the qtr to qtr decline in sales and profit.

    I guess I am in for the long long haul. :)
  • t
    thomas
    “Results demonstrate exceptional accuracy is achievable with the Accuray-only Synchrony® Lung Tracking™ with Respiratory Modeling
  • G
    Gregg
    Tue, April 27, 2021, 1:07 PM

    More content below

    ARAY
    -3.45%
    SUNNYVALE, Calif., April 27, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the third quarter of fiscal 2021 ended March 31, 2021.

    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)
    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)
    Third Quarter Fiscal 2021 Summary

    Net revenue of $102.6 million including $24.9 million of system revenue in China

    Gross orders of $87.4 million, an increase of 16 percent from the second quarter of fiscal 2021

    GAAP operating income of $4.4 million, GAAP net loss of $0.4 million, and Adjusted EBITDA of $8.7 million

    Received Shonin regulatory approval in Japan for ClearRT™ Helical kVCT Imaging for the Radixact® System

    "Our third quarter performance continues to reflect the positive momentum our business is making despite the headwinds created by the COVID-19 environment," said Josh Levine, President and CEO of Accuray. "Highlights from our third quarter performance include the continued ramp of China Type A system revenue, excellent progress in the phased introduction of ClearRT Helical kVCT Imaging platform for the Radixact System including regulatory approval in Japan and the continued adoption of our latest innovations like Synchrony real-time motion tracking and delivery adaptation on Radixact and our latest generation Cyberknife S7 system. Additionally, as announced yesterday, we are very excited to have Dr. Jean-Phillipe Pignol join us as Chief Medical and Technology Officer as we continue to build out our executive leadership team."
  • S
    Scott
    Check out the institutional ownership on marketbeat. They keep deleting my link. Institutional purchases drastically outweigh sales.

    https://www.marketbeat.com/stocks/NASDAQ/ARAY/institutional-ownership/
  • k
    kris
    Mms are on it low volume and the price going lower ... don't get it may be scaring the long term holders😀 go arayy
  • t
    thomas
    Pretty much in line with estimates. Although $25m in system revenue from China is impressive for sure
  • k
    kris
    IMHO it's surely mms trying to bring the pps lower with low volume.. don't see small caps with such good tech like aray and vray all others are already bought 😀
  • G
    Gregg
    Accuray Incorporated (NASDAQ: ARAY) announced today that the innovative ClearRT™ helical fan-beam kVCT imaging* capability has now been in clinical use for over two months, and is on track to expand into other markets. ClearRT on the Radixact® System is believed to have the potential to change the field of radiation oncology by enabling clinicians to easily, quickly and cost effectively acquire diagnostic-like quality CT images that enable them to "See More, Know More, and Do More," when treating tumors with radiation.
    Bullish
  • k
    kris
    Good numbers from china...and they need to move higher each quarter ..huge market and a very strong partner in china should help Aray..jmho